The present disclosure generally relates to therapies involving immune effector cells such as T cells engineered to express antigen receptors such as T cell receptors (TCRs) or chimeric antigen receptors (CARs). It is demonstrated herein that such antigen receptor-engineered immune effector cells may be generated in vitro/ex vivo as well as in vitro by delivering nucleic acid encoding an antigen receptor for genetic modification to cells using particles comprising the nucleic acid and a targeting molecule for targeting the immune effector cells, wherein the targeting molecule is a designed ankyrin repeat protein (DARPin). In particular, DARPins are described herein which are high-affinity binders for CDS binding to the CDS receptor on human and non-human primate (NHP) cells. Nanoparticles functionalized with CD8− targeting DARPins (CDS-DARPin) can deliver genes exclusively and specifically to human CD8.sup.+ T cells in vitro and in vivo.

Antibody particles are disclosed comprising polypeptides comprising an (Fc) binding domain, a helical polypeptide monomer, and an oligomer domain, and either Tie2 antibodies or dimers, or tumor necrosis factor receptor superfamily antibodies, and uses thereof.

Systems and methods to increase the efficacy of vaccines that require or are rendered more effective with T cell mediated immunity are described. The systems and methods utilize polynucleotides that genetically modify T cells to express a T cell receptor specific for an administered vaccine antigen.

A medical device includes a body defining an exterior surface, and a coating including a therapeutic agent-containing nanoparticle disposed on the exterior surface of the medical device. The nanoparticle may include a brush-arm star polymer. The therapeutic agent may be paclitaxel.

Provided is a cardiovascular implant based on in-situ regulation of immune response and a method for making the same, belonging to the technical field of biomedicine. The cardiovascular implant includes a cardiovascular implant body and H4000-CD25/dcas9 sustained-release nanoparticles modified on the cardiovascular implant body; the H4000-CD25/dcas9 sustained-release nanoparticles include an H4000 plasmid nanocarrier (Engreen), an anti-CD25 antibody, and a dcas9 plasmid sequence; a method for preparing the cardiovascular implant includes: constructing a cardiovascular implant body, preparing an H4000-CD25 nanotransfection vector, preparing H4000-CD25/dcas9 sustained-release nanoparticles, and conjugating the H4000-CD25/dcas9 sustained-release nanoparticles on the cardiovascular implant body. The present disclosure aims to construct a cardiovascular implant modified with the H4000-CD25/dcas9 sustained-release nanoparticles, which may induce nerve fiber ingrowth into engineered blood vessels; with the regulation ability of Treg cells on immune response, antithrombotic function of the cardiovascular implant is improved and in-situ regeneration of the cardiovascular implant is promoted.

Described herein are compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic. Also described are lyophilized compositions of antibodies and carrier proteins and methods of making and using the same, in particular, as a cancer therapeutic.

Disclosed are polynucleotides, compositions, and methods related to RNA interference (RNAi). The disclosed polynucleotides, compositions, and methods may be utilized for treating diseases and disorders through RNAi. Particular disclosed are toxic RNAi active seed sequences and methods of using toxic RNAi active sequences for killing cancer cells. The disclosed toxic RNAi active seed sequences preferentially target and inhibit the expression of multiple essential genes for cell survival and/or growth through a process called “death-induced by survival gene elimination” or “DISE.”

The present invention relates to proteins suitable for being used as scaffolds to which a peptide of interest is bound, or which are comprised within a conjugate to which an agent of interest is attached. It also relates to said conjugates suitable for the selective delivery of their conjugated agents of interest to specific cell and tissue types, wherein said agent 5 can be a therapeutic agent or an imaging agent. It also relates to nanoparticles comprising such conjugates and the therapeutic uses thereof.

[Object]

To provide a derivative of a short chain fatty acid that can exhibit physiological functions inherent in the short chain fatty acid.

[Solution]

Provided is a block or graft copolymer including a hydrophobic segment of a repeat unit containing a short chain fatty acid ester that is hydrolyzable by esterase in vivo and a hydrophilic segment including a poly(ethylene glycol) chain. These copolymers are effective in the treatment or therapeutic treatment of various diseases or disorders, including cancer.

The present inventions relates to a method for vision restoration comprising the steps of expressing a temperature-sensitive transient receptor potential (TRP) channel having an extracellular tag in the retina of a subject and of contacting said retina with a nanomaterial conjugated to a molecule specifically binding to said extracellular tag, wherein said nanomaterial generates heat by absorbing radiations of a specific wavelength. And reagents therefor.